Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,301 Mln
Revenue (TTM)
$249 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
8.5
Industry P/E
61.46
EV/EBITDA
-24.6
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$7
EPS
$-1.7
Face value
--
Shares outstanding
55,328,700
CFO
$-337.88 Mln
EBITDA
$-323.86 Mln
Net Profit
$-362.77 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Procept Biorobotics Corp (PRCT)
| -25.2 | 1.6 | 4.2 | -2.9 | 17.3 | -- | -- |
|
BSE Sensex*
| 4.5 | 1.0 | 6.3 | 5.9 | 16.4 | 18.6 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Procept Biorobotics Corp (PRCT)
| 91.1 | 0.9 | 66.1 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Procept Biorobotics Corp (PRCT)
|
60.2 | 3,300.9 | 249.1 | -90.2 | -34.6 | -28.6 | -- | 8.5 |
| 13.6 | 9,247.0 | 6,685.2 | 715.6 | 16.4 | 12.3 | 13 | 1.5 | |
| 250.1 | 6,628.2 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 1.0 | |
| 236.7 | 6,325.6 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 0.9 | |
| 57.9 | 7,834.4 | 2,510.8 | 185.6 | 8.8 | 4.5 | 43.2 | 1.9 | |
| 72.0 | 8,997.9 | 12,669.0 | 407.0 | 5.4 | 11.8 | 22.4 | 2.7 | |
| 165.2 | 8,955.9 | 1,973.6 | -494.5 | -11.4 | -41 | -- | 9.3 | |
| 256.9 | 9,952.9 | 1,240.1 | 42.2 | 4.1 | 3.6 | 238 | 8.2 | |
| 117.7 | 14,455.8 | 3,357.5 | 396.9 | 16.3 | 5.4 | 41.5 | 2.6 | |
| 118.9 | 6,677.4 | 645.7 | -25.4 | 6.8 | -1.3 | -- | 3.6 |
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided,... surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. Read more
President, CEO & Director
Dr. Reza Zadno Ph.D.
President, CEO & Director
Dr. Reza Zadno Ph.D.
Headquarters
San Jose, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Procept Biorobotics Corp (PRCT) stood at $ 571 Mln as on 31-Mar-25
The share price of Procept Biorobotics Corp (PRCT) is $60.22 (NASDAQ) as of 20-Jun-2025 16:00 EDT. Procept Biorobotics Corp (PRCT) has given a return of 17.32% in the last 3 years.
Procept Biorobotics Corp (PRCT) has a market capitalisation of $ 3,301 Mln as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Procept Biorobotics Corp (PRCT) is 8.48 times as on 20-Jun-2025, a 141% premium to its peers’ median range of 3.52 times.
Since, TTM earnings of Procept Biorobotics Corp (PRCT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Procept Biorobotics Corp (PRCT) and enter the required number of quantities and click on buy to purchase the shares of Procept Biorobotics Corp (PRCT).
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
The CEO & director of Dr. Reza Zadno Ph.D.. is Procept Biorobotics Corp (PRCT), and CFO & Sr. VP is Dr. Reza Zadno Ph.D..
There is no promoter pledging in Procept Biorobotics Corp (PRCT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,113
|
|
|
995
|
|
|
906
|
|
|
889
|
|
|
883
|
|
|
777
|
|
|
708
|
|
|
663
|
|
|
663
|
| Procept Biorobotics Corp (PRCT) | Ratios |
|---|---|
|
Return on equity(%)
|
-28.62
|
|
Operating margin(%)
|
-34.59
|
|
Net Margin(%)
|
-36.2
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Procept Biorobotics Corp (PRCT) was $0 Mln.
$0.56
(
